1-3 of 3
Christopher E. Wee, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience

Marissa Li, MD, Erika Morsia, MD, Christopher E. Wee, MD, Kristen McCullough, PharmD, Aref Al-Kali, MD, William J Hogan, MB, BCh, Mrinal M. Patnaik, MDMBBS, Ayalew Tefferi, MD, Naseema Gangat, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-137505
Published: 2020
Journal Articles

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Christopher E. Wee, MD, Jilan Kubusek, PharmD, Irbaz Riaz, MDMMSc, Robert Wolf, PharmD, RPh, Julian R Molina, MD PhD, Naseema Gangat, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2138.
https://doi.org/10.1182/blood-2019-127367
Published: 2019
Journal Articles

What's in a Name? a Gender-Based Analysis of Speaker Introductions at the American Society of Hematology Annual Meeting

Urshila Durani, MDMPH, Narjust Duma, MD, Jessica A Slostad, MD, Christopher E. Wee, MD, Yael Kusne, MD PhD, Shruti Patel, MD, Carolina Bernabe, MD, Ana Velazquez, MD, Cynthia Brooke Woods, DO, Martina C. Murphy, MD, Miriam Knoll, MD, Shikha Jain, MD, Stephanie L. Graff, MD, Ariela L. Marshall, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3411.
https://doi.org/10.1182/blood-2019-131484
Published: 2019